Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

author
created [InstanceEdit:9700279] Jassal, Bijay, 2020-09-15
dbId 9700232
displayName Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
journal Lancet
modified [InstanceEdit:9773716] D'Eustachio, Peter, 2022-05-09
pages 1940-1948
pubMedIdentifier 31679946
schemaClass LiteratureReference
title Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
url http://www.ncbi.nlm.nih.gov/pubmed/31679946
volume 394
year 2019
Cite Us!